INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03FWFogarty Patrick W0B / 90S90 trades$362K
  4. 04SJSheena Jonathan0B / 57S57 trades$3.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 32S32 trades$5.48M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,797 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
42 sh
Jan 12, 2026
Page 1464 of 1795
← PrevNext →
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

20
PD
Papadopoulos DidierPresident of Aircraft OEM
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,367 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

19
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC Form 4

Evidence

19
BG
Bowles GregoryChief Policy Officer
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$79K
5,383 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

19
HD
Hoops Elliot DeanGeneral Counsel and Secretary
MPMP Materials Corp. / DE
Tax withholding
F$296K
4,526 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

19
LA
Lopez Diaz AgustinSVP Chief Supply Chain Officer
SWKSTANLEY BLACK & DECKER, INC.
Grant or award
A—
61.9K sh
Dec 19, 2025Jan 14, 2026
traded Dec 19, 2025
+26dSEC Form 4

Evidence

19
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
3,800 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC Form 4

Evidence

19
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
3,800 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC Form 4

Evidence

19
KE
Kao John EDirector, Chief Executive Officer
ALHCAlignment Healthcare, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
2,727 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

19
HD
Hoops Elliot DeanGeneral Counsel and Secretary
MPMP Materials Corp. / DE
Tax withholding
F$590K
9,028 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

19
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
6,193 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC Form 4

Evidence

19
RA
Ryan Matthew AChief Marketing & Tech. Off.
HOGHARLEY-DAVIDSON, INC.
Grant or award
A—
62.2K sh
Dec 8, 2025Jan 14, 2026
traded Dec 8, 2025
+37dSEC Form 4

Evidence

19
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$77K
4,290 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$20K
240 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
140 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
447 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
WM
Wong Nelson MunpunSenior Vice President
KLICKULICKE & SOFFA INDUSTRIES INC
Open-market sale · 10b5-1 plan
SELL$1.70M
30.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$730
9 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$8,290
91 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$1,598
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$1,419
18 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$1,459
18 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$10K
115 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$13K
148 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$25K
290 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$9,166
109 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

18
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$3,691
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence